Peer Review History

Original SubmissionApril 12, 2022
Decision Letter - Sebsibe Tadesse, Editor

PONE-D-22-10807An Investigation of a Hundred COVID-19 Cases and Close Contacts in Ethiopia, May to June, 2020: A Prospective Case-ascertained StudyPLOS ONE

Dear Dr. Watare,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Aug 22 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Sebsibe Tadesse, PhD

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.

3. Thank you for stating the following financial disclosure:

 “This study was conducted as part of the routine national COVID-19 response efforts under the Ethiopian Public Health Institute. Thus, The author(s) received no specific funding for this work.”

At this time, please address the following queries:

a)        Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

b)        State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

c)        If any authors received a salary from any of your funders, please state which authors and which funders.

d)        If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

4. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

5. We note that Figures 1, 2 and 3 in your submission contain map images which may be copyrighted. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For these reasons, we cannot publish previously copyrighted maps or satellite images created using proprietary data, such as Google software (Google Maps, Street View, and Earth). For more information, see our copyright guidelines: http://journals.plos.org/plosone/s/licenses-and-copyright.

We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission:

 a. You may seek permission from the original copyright holder of Figures 1, 2 and 3 to publish the content specifically under the CC BY 4.0 license. 

We recommend that you contact the original copyright holder with the Content Permission Form (http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf) and the following text:

“I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (http://creativecommons.org/licenses/by/4.0/). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.”

Please upload the completed Content Permission Form or other proof of granted permissions as an "Other" file with your submission.

In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].”

 b. If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.

The following resources for replacing copyrighted map figures may be helpful:

USGS National Map Viewer (public domain): http://viewer.nationalmap.gov/viewer/

The Gateway to Astronaut Photography of Earth (public domain): http://eol.jsc.nasa.gov/sseop/clickmap/

Maps at the CIA (public domain): https://www.cia.gov/library/publications/the-world-factbook/index.html and https://www.cia.gov/library/publications/cia-maps-publications/index.html

NASA Earth Observatory (public domain): http://earthobservatory.nasa.gov/

Landsat: http://landsat.visibleearth.nasa.gov/

USGS EROS (Earth Resources Observatory and Science (EROS) Center) (public domain): http://eros.usgs.gov/#

Natural Earth (public domain): http://www.naturalearthdata.com/

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: These are my comments for a manuscript entitled: An Investigation of a Hundred COVID-19 Cases and Close Contacts in Ethiopia, May to June, 2020: A Prospective Case-ascertained Study.

Overall, there is indeed value to publish this manuscript, as a way to promote research in the African region & also adding another data point for WHO's FFX protocol usage in Ethiopia. However, there are several critical issues that the authors should address, particularly in the methods section.

Critically, I find it worrying that there is no mention at all, on the definitions for the measures reported in this manuscript. Measures such as the secondary attack rate, secondary clinical attack rate, incubation period, serial interval (SI) should be included in the Statistical analysis sub-section. How was the reproduction number estimated? Also, how were the 10 clusters identified for SI calculation? Puzzlingly, the 10 clusters were only mentioned in the results.

Please also clarify the following for the methods sections:

1. How were the 3 contacts "randomly selected" for the study? If household size information was also collected, I suggest to report them in your results, so that international readers can roughly gauge the impact of choosing 3 contacts rather than enrolling all contacts into the study.

2. Please mention also the contact settings included in the study (this is only mentioned in table 5 results).

3. As it is mentioned that "a review of medical records" was done, clarify as well what was reviewed? Is this where co-morbidity conditions were checked for all cases?

4. It is mentioned that a symptom diary was collected. What was the use of this diary? If contacts develop symptoms during the 14 day follow-up, were they tested?

5. Please clarify if ethical review was done for this study. Or if it is waived as the study was conducted as part of the routine national COVID-19 response efforts under the Ethiopian Public Health Institute. If the latter is true, do include it in the ethics subsection of the main text.

For the results section, some tables are not informative to justify its use; it can be removed and written in text format. Such as Tables 2 & 3.

For the discussion section,

1. Check if the studies used to be compared with this study's findings are in fact comparable. Because it doesn't seem reasonable to compare proportions from this study (n=100) against much larger studies (n=1000 to 10000). I suggest to compare against existing FFX results from other countries.

2. Do mention any limitations for this study.

3. "This will facilitate timely estimates of the severity and transmissibility of COVID-19 infection. The finding will also inform public health responses and policy decisions in developing appropriate response strategies." I agree of the study's appropriateness to fulfil the above-mentioned study rationale. It will be interesting for international readers to learn what happen in Ethiopia (or at the capital city), after the first 100 cases. Were the results translatable to what happened after first 100? And if these result were ready in the timely manner, how did it help inform public policy makers at that time?

4. Can you suggest how would these results help to inform public policy makers under the current Omicron variant circulation?

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

We would like to acknowledge the reviewer for the critical review. We have included all the required information as per the reviewer’s comment/suggestion in the method part.

The ten clusters are selected for SI calculation because only contacts in these clusters tested positive and transmission of disease from index to contacts is required to perform SI estimation/calculation.

The three contacts were selected randomly using lottery method, we have now included it in the method section. However, the household size information was not collected. It is also not indicated in WHO’s FFX protocol.

The contact settings incorporated under the study population and period sub section of the method section.

We clarify about which medical record has been reviewed in the data collection sub section. Yes, the comorbidities for all cases were checked in this record but also all the cases were asked for comorbidities during interview.

Symptom diary was done to check if the contacts develop symptom during the follow up period and will be tested if they develop any sign and symptoms of COVID 19.

We have clarified that the ethical review is waived as the study was conducted as part of the routine national COVID-19 response efforts under the Ethiopian Public Health Institute.

We compared our findings with similar publications of comparable study participants. In addition, we have also discussed our findings comparing with studies of similar subject matter but high number of study participants. Our study participants are also 400 (100 cases and 300 close contacts).

We do include the limitations for this study at the last paragraph of the discussion section.

The result of this study was available on time and the national COVID 19 preparedness and response plan and the response strategy was revised based on this finding.

Thanks for this very important question. Indeed, this study was done without considering the variants of COVID 19.

The detail explanation is attached in the Rebuttal letter in this submission.

Attachments
Attachment
Submitted filename: Rebuttal letter_Response to Reviewers.docx
Decision Letter - Sebsibe Tadesse, Editor

An Investigation of a Hundred COVID-19 Cases and Close Contacts in Ethiopia, May to June, 2020: A Prospective Case-ascertained Study

PONE-D-22-10807R1

Dear Dr. Shambel Habebe Watare,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Sebsibe Tadesse, PhD

Academic Editor

PLOS ONE

Formally Accepted
Acceptance Letter - Sebsibe Tadesse, Editor

PONE-D-22-10807R1

An investigation of a hundred COVID-19 cases and close contacts in Ethiopia, May to June, 2020: A prospective case-ascertained study

Dear Dr. Watare:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Sebsibe Tadesse

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .